The World Health Organisation (WHO) has raised concern over the stagnation of global HIV prevention efforts, announcing ...

The World Health Organisation (WHO) has endorsed the use of the long-acting injectable antiretroviral drug lenacapavir for ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

For some people, HIV feels like something that happens to “other people.” It’s a distant issue — something for a different ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

The loss of federal funding from the Centers for Disease Control comes as Memphis health officials face rising rates of new ...

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...